在一项1000万美元的股票投资为关键睡眠呼吸暂停试验后, Incannex医疗保健的股票跌了37.5%. Incannex Healthcare's stock fell 37.5% after a $10M share offering to fund a key sleep apnea trial.

在宣布直接出售200万股票和证券, 价值1000万美元后, Incannex医疗保健股价下跌37.5%,至3.73美元, 潜在的筹集额达2300万美元. Incannex Healthcare shares dropped 37.5% to $3.73 after announcing a $10 million direct offering of 2 million shares and warrants, potentially raising up to $23 million. 这些资金将支持第二阶段的DReAMzz交叉研究,用于IHL-42X,这是一种用于阻塞性睡眠呼吸暂停的口服治疗,该研究的第二阶段RePOSA结果呈阳性,并获得FDA快速指标. The funds will support the Phase 2 DReAMzz crossover study for IHL-42X, an oral treatment for obstructive sleep apnea, following positive Phase 2 RePOSA results and FDA Fast Track Designation. 该公司正在优化新研究中的剂量比率,以提高效益并简化今后的开发,目的是进行更有效的第三阶段试验。 The company is optimizing dosing ratios in the new study to improve efficacy and streamline future development, aiming for a more efficient phase 3 trial. 尽管临床开发取得进展,但股票下降反映出投资者对股票稀释的关切。 The stock decline reflects investor concern over share dilution despite progress in clinical development.